Research and Development
This group unites PF patients, caregivers, researchers and medical professionals in a platform to... View more
Organizer:
- Organized by
-
-
Study: Real-World Data Support Use of Ofev in IPF Management
-
Study: Real-World Data Support Use of Ofev in IPF Management
Real-world data shows that treatment with Ofev (nintedanib, marketed by Boehringer Ingelheim) helps stabilize idiopathic pulmonary fibrosis (IPF) and is well-tolerated, a German study reports.
The research, “Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis,” was published in the journal Respiration.
Ofev and Esbriet (pirfenidone, marketed by Genentech) are the two currently approved anti-fibrotic therapies for patients with IPF. Ofev blocks tyrosine kinase, a critical enzyme for cellular signaling pathways that leads to excess release of growth factors in IPF patients. These molecules promote collagen deposition, as well as maturation and multiplication of cells called fibroblasts, which lead to lung fibrosis.
Prior clinical studies have shown that twice-daily treatment with 150 mg Ofev reduced the decline in lung function and prolonged the time to first acute disease exacerbation in IPF patients. This led to Ofev’s approval for IPF treatment for adults in the U.S. and Europe.
Read more about this news here: “Real-World Data Support Use of Ofev in IPF Management, Study Finds“
-
0 Replies
Sorry, there were no replies found.
Log in to reply.